Recruiting PHASE3 INTERVENTIONAL 1-arm NCT06401356

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Sponsor: Novartis Pharmaceuticals

Conditions Advanced Malignancies Hematologic Malignancy Solid Tumor

Interventions Pelabresib

Updated 7 times since 2024 Last updated: Jun 17, 2025 Started: Aug 13, 2024 Primary completion: Jun 2, 2027 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Advanced Malignancies and Hematologic Malignancy, this trial is actively recruiting participants. The trial is conducted by Novartis Pharmaceuticals and has accumulated 7 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Jul 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Jan 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE3

▶ Show 2 earlier versions

Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ann Arbor, United States , Antwerp, Belgium , Bruges, Belgium , Cardiff, United Kingdom , Chicago, United States , Florence, Italy , Glasgow, United Kingdom , Jacksonville, United States , London, United Kingdom and 4 more locations